Filing Flows › Gyre Therapeutics (GYRE) › Q3 2025
Gyre Therapeutics (GYRE) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Gyre Therapeutics (GYRE) reported revenue of $30.6M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +14% from the quarter before. Operating margin was 22.7%, net earnings $5.9M (19.4% of revenue).
Gyre Therapeutics, Q3 2025: revenue $30.6M (+20% year over year), operating margin 22.7%, net earnings $5.9M, operating cash flow $4.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $30.6M | +14% | +20% |
| Gross profit | $28.9M | +13% | +18% |
| Operating profit | $6.9M | +219% | +64% |
| Net earnings | $5.9M | +277% | +108% |
| Operating cash flow | $4.7M | +124% | +171% |
| Free cash flow | $4.0M | +119% | +288% |
What changed
Revenue was $30.6M in Q3 2025, up 20% year over year and up 14% from the previous quarter.
Gross margin was 94.7%, down 1.6 points from a year earlier. Operating profit was $6.9M, a 22.7% margin (up 6.0 points year over year). Of the extra revenue versus a year earlier, 53% reached operating profit, above the 17% margin then. Operating expenses grew 8% against revenue growth of 20%. The fastest-growing cost line was General & admin (+13%). Net earnings were $5.9M, up 108% year over year. The effective tax rate was 22.2%.
Operating cash flow was $4.7M (up 171% year over year), 79% of net earnings. Non-cash charges added back $649K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items used $3.1M. Capital expenditures of $668K left free cash flow of $4.0M.
Questions
What was Gyre Therapeutics' revenue in the third quarter 2025?
Gyre Therapeutics (GYRE) reported revenue of $30.6M for the third quarter 2025 (Q3 2025), +20% from a year earlier and +14% from the quarter before.
Was Gyre Therapeutics profitable in the third quarter 2025?
Operating profit was $6.9M (22.7% of revenue) and net earnings $5.9M.
Source: Gyre Therapeutics 10-Q on SEC EDGAR.